A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

Inclusion Criteria

• Inclusion Criteria for DSG3-CAART: Closed to enrollment - Confirmed diagnosis of mPV by prior or screening biopsy and prior positive anti- DSG3 antibody ELISA - mPV inadequately managed by at least one standard immunosuppressive therapies - Active mPV at screening - Anti-DSG3 antibody ELISA positive at screening Inclusion Criteria for CABA-201 sub-study: Open to enrollment - Age ≥18 - Confirmed diagnosis of PV by prior or screening biopsy and prior positive DSG3 ELISA, IIF, and/or DIF - PV inadequately managed by at least one standard immunosuppressive therapy - Active PV at screening - DSG3 ELISA positive at screening Exclusion Criteria: - Active cutaneous lesions associated with PV that indicates mucocutaneous rather than mucosal-dominant disease - Rituximab in last 12 months unless PV symptoms have recently worsened or anti-DSG3 antibody titers have recently increased - Prednisone > 0.25mg/kg/day - Other autoimmune disorder requiring immunosuppressive therapies - Investigational treatment in last 3 months Exclusion Criteria for CABA-201 sub-study - Have paraneoplastic pemphigus or active malignancy (not including non-melanoma skin cancer) or malignancy diagnosed within the previous 5 years - Have received rituximab or other anti-CD20 or anti-CD19 therapies in last 12 months unless anti-DSG3 antibody titers have recently increased or PV symptoms have recently worsened - Prednisone > 0.25mg/kg/day - Other autoimmune disorder requiring immunosuppressive therapies - Treatment with any investigational agent within 4 weeks or 5 half-lives, whichever is longer.